Buy & Sell RLX Technology Inc (RLX) – RLX Technology Inc Price Today
Aura AI Summary
Key Stats
- $2.57BMarket Cap
- TechnologySector
- -14.34%3M Drawdown
- $1.12BEnterprise Value
- 4.76%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 4 daysTypical Hold Time
RLX Technology Inc (RLX) is currently valued at a market capitalization of $2.57B, with an enterprise value of $1.12B. Over the past 52 weeks, RLX Technology Inc has traded between a low of $1.87 and a high of $2.73, highlighting its annual price range. Over the past three months, RLX Technology Inc has recorded a drawdown of -14.34%, reflecting recent price volatility. RLX Technology Inc offers a dividend yield of 4.76%. On average, investors hold RLX Technology Inc for approximately 4 days, indicating typical investor behavior on the platform.
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Most Recent News
Nvidia commits $40B to AI investments in early 2026, including $30B in OpenAI
Nvidia has invested over $40 billion in AI-related equity deals in early 2026, with a major $30 billion stake in OpenAI. The company also made multi-billion dollar investments in public firms like Corning and IREN, signaling strong confidence in the ...
Investor Michael Burry warns AI stock craze mirrors late 1990s Dot-com bubble risks.
Michael Burry, known for predicting the 2008 housing crash, warns that the current stock market rally driven by enthusiasm for AI-related companies resembles the late 1990s Dot-com bubble. Despite economic uncertainty, major U.S. indexes keep hitting...
BioVie nears data readout for potential first treatment targeting long COVID symptoms.
BioVie Inc is advancing its clinical trial for a novel treatment aimed at long COVID, a condition affecting around 17 million Americans with symptoms like brain fog and fatigue. The company has secured a $13 million grant, making it unique in receivi...